Quanterix (QTRX)
(Delayed Data from NSDQ)
$13.28 USD
+0.63 (4.98%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $13.27 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.28 USD
+0.63 (4.98%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $13.27 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Zacks News
Strength Seen in Quanterix Corporation (QTRX): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 26.87% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Quanterix Corporation (QTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 20.29% and 1.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.68% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cassava (SAVA) Down on Report of SEC Investigation Into AD Program
by Zacks Equity Research
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quanterix Corporation (QTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cassava (SAVA) Down as Quanterix Issues Statement on AD Study
by Zacks Equity Research
Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -3.13% and 7.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Quanterix Corporation (QTRX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Quanterix Corporation (QTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -3.33% and 3.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
How Quanterix (QTRX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Quanterix (QTRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.